SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1756)2/26/2003 6:03:22 PM
From: Biomaven  Read Replies (1) | Respond to of 2243
 
>> I'm sure you noticed the patent on S is a big issue. An oral agent expiring '09/'10, with NDA not expected until '06? That's not much time to see the off-label adoption they hope for. What patent extension strategy do you think they have in mind?>>

Well I'm guessing they would get a full 5 year patent life extension if the drug is approved.

(Know nothing about the drug itself, just talking generally here).

Pete



To: Icebrg who wrote (1756)2/26/2003 7:30:15 PM
From: keokalani'nui  Respond to of 2243
 
Plus, $2m milestone when P3 starts, which is pretty much assured. Right?

BTW, some--not much--further discussion about the patent on Q#2 following presentation. Made it sound like Japan is longer (10 years or so), other minor points escaped me.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News